Abstract 88P
Background
The impact of bilateral mastectomy in women diagnosed with unilateral breast cancer on reduced deaths from breast cancer is a subject of considerable interest. We sought to estimate the 20-year risk of breast cancer mortality among women with Stage 0 to Stage III unilateral breast cancer according to the type of surgery performed (lumpectomy, unilateral mastectomy, bilateral mastectomy).
Methods
We identified 661,270 women with unilateral breast cancer in the Surveillance, Epidemiology, and End Results (SEER) 17 database diagnosed from 2000 to 2019. From these, we generated three closely matched cohorts of equal size using 1:1:1 generalized propensity score matching by surgery performed. Matched subjects were followed for 20 years for contralateral breast cancer and for breast cancer mortality.
Results
There were 661,270 eligible cases of unilateral breast cancer in our cohort, of which 39,736 (6.0%) underwent a bilateral mastectomy. After matching, we retained three similar cohorts of equal size (n = 36,028). The 20-year cumulative risk of contralateral breast cancer was 7.8% in the lumpectomy group, 6.1% in the unilateral mastectomy group, and 0.7% in the bilateral mastectomy group. In a combined lumpectomy/unilateral mastectomy group, the breast cancer mortality rate was higher after developing a contralateral cancer (HR, 4.00; 95% CI, 3.52-4.54). The 20-year breast cancer mortality was 16.3% in the lumpectomy group, 16.7% in the unilateral mastectomy group, and 16.7% in the bilateral mastectomy group.
Conclusions
The risk of dying of breast cancer increases significantly after experiencing a contralateral breast cancer. Women with breast cancer treated with bilateral mastectomy had a greatly diminished risk of contralateral breast cancer, but experienced similar mortality rates as those patients treated with lumpectomy or unilateral mastectomy.
Legal entity responsible for the study
The authors.
Funding
PRiME-Women’s College Hospital Clinical Catalyst Program; Canadian Cancer Society; Canada Institutes of Health Research; Peter Gilgan Centre for Women’s Cancers.
Disclosure
All authors have declared no conflicts of interest.